Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.56 |
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA7 | P43166 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560944 | 1.00 | CA1 (0.56) | CA1CA2CA7CA9CA14 | |
| SCHEMBL21063713 | 0.78 | CA1 (0.51) | CA1CA2CA7CA9CA14 | |
| SCHEMBL22776229 | 0.76 | MAPK10 (0.56) | CA1CA2CA7CA9CA14 | |
| SCHEMBL22777241 | 0.76 | MAPK10 (0.56) | CA1CA2CA7CA9CA14 | |
| SCHEMBL29560957 | 0.76 | MAPK10 (0.56) | CA1CA2CA7CA9CA14 | |
| SCHEMBL6718222 | 0.76 | CA1 (0.47) | CA1CA2CA7CA9CA14 | |
| SCHEMBL6721143 | 0.74 | MAPK10 (0.51) | CA1CA2CA7CA9CA14 | |
| SCHEMBL6720528 | 0.73 | MAPK10 (0.53) | CA1CA2CA7CA9CA14 | |
| SCHEMBL6724633 | 0.73 | ALDH1A1 (0.47) | CA1CA2CA7CA9CA14 | |
| SCHEMBL7213740 | 0.73 | UCHL1 (0.53) | CA1CA2CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | CA1 4605/4885CA2 4850/4885CA7 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.